Following the collaboration with InnoMed, Kossel Medtech has taken another step in building its globalfocused ecosystem.

Kossel Medtech (Suzhou) Co., Ltd. (“Kossel Medtech”) recently entered into a strategic cooperation agreement with Suzhou Silvan Medical Co., Ltd. (“Silvan Medical”). Under the agreement, Kossel Medtech will hold exclusive responsibility for the overseas commercial rollout of Silvan Medical’s Clothoid Vascular Closure System. Parallel efforts will cover global and domestic regulatory registration as well as joint technical development. From peripheral drugcoated balloons to vascular closure systems, a series of industrial integrations and ecosystem deployments illustrate Kossel’s evolving platform strategy: its globalmarket capabilities are expanding from supporting only its own products toward shared ecosystem. With successive partnership deliveries, this collaborative globalization pathway for innovative Chinese medical device manufacturers is broadening and gaining momentum.

Channel Synergy: The Inflection Point for a ChineseOrigin Vascular Closure System Going Global

Vascular access puncture sites mark both the starting point and endpoint of interventional procedures.

As a Vascular Closure Device (VCD), the vascular closure system converts conventional opensurgical suturing into minimallyinvasive percutaneous intervention. It delivers precise mechanical closure of puncture sites via suture material, featuring rapid hemostasis, reliable clinical outcomes and reduced complication rates. Gradually replacing manual compression, it is becoming the standard hemostatic solution for interventional surgeries. Against the backdrop of population ageing and rising cardiovascular disease prevalence, minimallyinvasive interventional volumes keep increasing worldwide, driving urgent clinical demand for safe, efficient and standardized vascular closure modalities.

Nevertheless, the global vascular closure system market has long been dominated by a small number of international giants. Incumbent advantages coupled with technical barriers have left domestic Chinese products barely visible in overseas markets. Against this landscape, Silvan Medical’s Clothoid Vascular Closure System has achieved the challenging initial breakthrough for domestic devices: completing the “zerotoone” journey for global market entry. Founded under the leadership of renowned biomaterials expert Professor Yang Ke, Silvan Medical translates original material innovations into vascularinterventional clinical solutions, and Clothoid represents one such key translational output. The product has navigated critical milestones spanning registration and hospital adoption: it has obtained CE certification, secured regulatory validation in more than ten countries, and achieved initial commercial traction.

The swift conclusion of the KosselSilvan partnership stems from the fact that Clothoid sits exactly at the validated, scalingready inflection point.

For Silvan Medical, superior clinical performance enabled its zerotoone breakthrough. However, scaling from one to one hundred requires more than a highquality product. Building global distribution networks independently would involve lengthy timelines, high costs and substantial uncertainties. Kossel Medtech’s commercial footprint covering over 20 countries and regions delivers the missing piece: it can convert proven localmarket validation into systematic global coverage.

For Kossel Medtech advancing its Local Base, Global Reach strategy, this partnership carries equally clear value. Silvan’s existing overseas channel resources and established clinicalexpert awareness provide prevalidated market access for Kossel. This mutuallyempowering industrial integration empowers the two Chinese enterprises to compete systematically within a segment long controlled by foreign players, combining differentiated product strengths and channel capabilities to move beyond isolated breakthroughs toward systematic competitiveness.

FourStep SingleOperator Vascular Closure: Completing the Final Link in Interventional Workflows

Clothoid’s core value proposition can be summarized as simple operation with predictable safety performance.

In terms of procedural workflow, Clothoid adopts pretied suture design and eliminates intraoperative manual knottying. The full procedure can be completed by one operator in four sequential steps: actuate the lever to open the foot; advance needles precisely through the vascular wall to accomplish puncture and suture encirclement; retract the device and tighten external knots to seal the vascular puncture; confirm hemostasis and trim excess extracorporeal suture material to finish vascular closure.

Clinically, intraprocedural hemostasis confirmation is feasible. Patients can ambulate immediately postprocedure without prolonged bed rest, while requirements for analgesics and urinary catheterization are markedly reduced. Patient comfort and clinical satisfaction are improved, enabling true fasttrack rehabilitation after minimallyinvasive intervention.

In application scope, Clothoid is indicated for closure of common femoral artery and common femoral vein puncture sites. It accommodates sheath sizes from 5 F up to 21 F for arterial access and 5 F to 24 F for venous access, covering diagnostic catheterization as well as largebore interventional therapies for structural heart disease.

Field feedback indicates multiple key performance metrics of Clothoid outperform imported benchmarks. Its vascular closure success rate reaches 96 %, and device failure incidence is approximately half that of comparable imported alternatives.

Adding this product brings clear strategic logic to Kossel Medtech’s global panvascular interventional portfolio.

Postprocedural puncturesite closure constitutes the final step for every vascular interventional case. Vascular closure systems featuring safety, efficiency and standardization have become essential tools boosting procedural efficiency and patient safety for complex interventions. Clothoid achieves seamless clinical alignment and fullworkflow complementarity with Kossel’s existing peripheral, coronary and electrophysiology product lines, further completing its endtoend vascularinterventional solution portfolio.

Per the cooperation agreement, Kossel Medtech will also pursue CEMDR and NMPA registration under its own brand. Amid volumebased procurement normalization, hospitals increasingly favor longterm suppliers capable of delivering onestop solution packages. Upon registration completion, Clothoid will combine with Kossel’s existing offerings to form integrated clinical solutions. Productmatrix synergy will expand clinical options while strengthening Kossel’s market resilience and comprehensive competitive edge.

A Replicable, Scalable GlobalExpansion Model Takes Shape

China’s medicaldevice industry is passing an inflection point in its industrial lifecycle. There are roughly 35 000 domestic manufacturers; the top10 Chinese firms post annual revenues ranging from RMB 4 billion to RMB 34 billion, whereas the top10 UnitedStatesbased peers operate at hundredbilliondollar revenue scale. The domestic sector remains in a fragmented growth phase. As volumebased procurement drives lowend homogenized capacity out of the market, resources keep concentrating toward leading and innovative enterprises. Industrial consolidation and collaborative development have become an irreversible trend.

From InnoMed to Silvan Medical and future industry partners, amid ongoing consolidation Kossel Medtech is reinforcing its platform value and building a winwin globaloriented ecosystem.

Regarding this collaboration, Kossel Medtech commented:

“China’s medicaldevice sector has entered a highqualitydevelopment phase characterized by resource consolidation and survival of the fittest. Indepth industrial integration and collaborative global expansion represent an inevitable industry trend. Silvan Medical delivers a robust product portfolio, and its offering is highly strategically complementary to Kossel’s panvascular focus and established globaloperation capabilities. This is more than a business linkage; it represents longterm deep strategic alignment. Kossel will fully commit to globalmarket development to support Chinese device manufacturers in achieving global breakthroughs. Building on solid mutual trust, we will advance multidimensional collaboration spanning R&D and material supply chains to foster a mutuallybeneficial industrial ecosystem.”

For Silvan Medical, rooted in cuttingedge material innovation, leveraging Kossel’s mature global distribution infrastructure enables faster engagement with worldwide clinical requirements. Resources can be further concentrated on product iteration and clinical optimization, accelerating translation from laboratory innovation to realworld surgical practice.

Silvan Medical expressed high expectations for this joint initiative:

“Since 2019 Silvan Medical has focused on vascular closure system development, targeting to break foreign giants’ dominance and realize domestic substitution for highend interventional devices. Our product demonstrates comprehensive performance superior to imported counterparts. Entrusting overseasmarket operations to Kossel reflects full recognition of its professional operational competency and global footprint. Moving forward Silvan Medical will prioritize technical R&D, lean manufacturing and cost optimization. Together with Kossel we will explore global markets, pursue frontier innovation, advance product iteration and joint technical development, bringing premium Chineseorigin medical devices to global clinical communities.”

Global market expansion will shape the next developmental phase of China’s medicaldevice industry.

Within a landscape of 35 000 manufacturers, technologydriven partnerships and channel complementarity are more than commercial decisions: they represent the macro trend toward ecosystemoriented industrial consolidation. Each industrial partnership and ecosystem deployment by Kossel Medtech further matures this globalexpansion system. It drives Chinese panvascular interventional device exports from individual product‑level breakthroughs toward deeper systematic value delivery, weaving a mutuallybeneficial network for global clinical impact.

References

1. Industrial‑Lifecycle Perspective: Consolidation and Competitiveness‑Enhancement Pathways for China’s Medical‑Device Industry. Arterial Network.
2. Manual Compression versus Vascular Closure Devices: Key Takeaways from CIRSE Consensus on Ultrasound‑Guided Access, VCD Selection and Complication Thresholds. NVVIMed.
3. Silvan Medical: Developing Antimicrobial Metallic Implants to Fill Domestic Gaps in High‑End Implantable Devices. Arterial Network.